Compare GGN & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GGN | CERT |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.0M | 860.9M |
| IPO Year | N/A | 2020 |
| Metric | GGN | CERT |
|---|---|---|
| Price | $5.14 | $5.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 470.7K | ★ 3.5M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 10.26% | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | N/A | $4.18 |
| Revenue Next Year | N/A | $5.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $4.31 | $4.45 |
| 52 Week High | $5.88 | $13.88 |
| Indicator | GGN | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 37.64 | 58.09 |
| Support Level | $5.09 | $5.19 |
| Resistance Level | $5.32 | $6.47 |
| Average True Range (ATR) | 0.07 | 0.36 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 21.25 | 88.68 |
GAMCO Global Gold Natural Resources & Income Trust is a non-diversified closed-end management investment company. Its primary investment objective is to provide a high current income and capital appreciation as its secondary objective. To achieve its objective, the fund may invest majority of its assets in equity securities of companies principally engaged in the gold and natural resources industries. It also intends to earn income through an option planning of writing (selling) covered call options on equity securities in its portfolio.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.